NCT05363891Phase 2Completed

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-10-31Actual

Enrollment · participants243Actual

Source updated2025-01-16Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Rheumatoid Arthritis

Treatments or interventions studied

NatrunixDrugAlso known as True Human IgG4 monoclonal antibody
PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: ACR 20 response rate at 12 weeks.; description: The ACR is a measure used in clinical practice and clinical trial to assess medication efficacy in patients with RA, by notating improvements in swelling and tenderness in designated joints, as well as improvements in at least 3 out of 5 other categories. The other categories assessed are patient global assessment of disease activity, physician global assessment of disease activity, patient reported pain scale, disability/functionality questionnaire response, and acute phase reactant levels (CRP and ESR).; timeFrame: At 12 weeks from baseline

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history